Acorda Therapeutics Announces Delisting from Nasdaq

Riskiest Junk Bonds Shunned in Europe on Rising Risk of Default

Acorda Therapeutics Announces Nasdaq Delisting Notification

Acorda files for bankruptcy, reveals asset sale plan

Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The Industry

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript

Acorda Therapeutics Reports Third Quarter 2023 Financial Results

Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023